Vendor Intelligence Report: Huaian Hanyou Peptide

Published 3 Jul 2026. 22-page investigative report on who is behind Huaian Hanyou Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 33 Finnrick lab tests, Huaian Hanyou Peptide has 23 passes and 10 failures, an overall pass rate of 70%. The number hides a wide split: Retatrutide is the strongest current case, reinforced by a separate high-purity Freedom Diagnostics COA from the genuine channel, while Tirzepatide looks usable on a thinner record. BPC-157 is weak and TB-500 is the clear avoid signal; ratings also contract under stricter grading.

The vendor-side investigation is equally uneven. SGS-referenced Global Sources records tie the market-facing peptide brand to a recently incorporated sporting-goods and rubber-products company, while the sales profile advertises a much longer peptide-manufacturing history, factory scale, and experience claims the registry trail does not verify.

The channel problem is the sharper buyer risk. The strongest genuine route appears to be the Global Sources and direct-contact path, but the public Facebook surface was captured under a generic Factory Direct-Peptides B name and no clean official-domain, reseller, batch-authentication, or anti-counterfeit system was observed. Community reporting also describes months-long delays, inactive tracking, mis-ships, and unlabeled product even on the genuine side.

A separate lookalike storefront using the Huaian Hanyou name presents a more acute scam vector: recent privacy-protected registration, WhatsApp funnels, generic US-style testimonials, propagation into secondary profiles, and fee-ladder payment demands documented in community and consumer-protection reporting. The full report separates that impersonation infrastructure from the genuine trading channel and shows how to avoid conflating the two.

Inside the full report:

  • Per-product pass/fail rates, trajectories, and methodology-divergence charts for all 4 tested products
  • SGS/Global Sources registry analysis of the sporting-goods entity behind the peptide brand
  • WHOIS/ICANN and hosting evidence for the lookalike Huaian Hanyou domain
  • Contact-pathway map covering Global Sources, Facebook, WhatsApp leads, and scam-side aliases
  • Community fulfillment record covering delays, tracking failures, mis-ships, and labeling complaints
  • Freedom Diagnostics Retatrutide COA and the unresolved Janoshik-search limitation

Risk assessment

  • Copycat / brand-confusion risk — high: Active huaianhanyoupeptides.com impersonation uses recent registration, fake reviews, rotating US WhatsApp numbers, BBB-reported losses, and Mia/Thomas fee-ladder aliases; no authoritative official-domain or anti-counterfeit guide was observed.
  • Genuine-channel fulfillment reliability risk — high: Buyer reports through the genuine route include months-long delays, fake or inactive tracking, poor communication, mis-ships, and unlabeled product.
  • Product-specific quality failure risk — high: Finnrick results are weak for TB-500 at 26.95% and BPC-157 at 48.25%; Retatrutide at 86.04% and Tirzepatide at 79.8% are materially stronger.
  • Corporate identity and manufacturer-claims mismatch risk — medium: SGS/Global Sources records show a 2024 sporting-goods/rubber-products entity with RMB 300,000 capital, while marketing claims 15 years, 2005 establishment, and a 3,000-square-meter factory with 60 employees.